Advice

following an abbreviated submission:

crovalimab (Piasky®) is accepted for restricted use within NHSScotland.

Indication under review: as monotherapy for the treatment of adult and paediatric patients 12 years of age or older with a weight of 40 kg and above with paroxysmal nocturnal haemoglobinuria (PNH):

  • In patients with haemolysis with clinical symptom(s) indicative of high disease activity.
  • In patients who are clinically stable after having been treated with a complement component 5 (C5) inhibitor for at least the past 6 months.

SMC restriction: under the advice of the national PNH service.

Crovalimab offers an additional treatment choice in the therapeutic class of complement C5 inhibitors.

Another complement C5 inhibitor was accepted for restricted use under the orphan equivalent process.

This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.

Download detailed advice279KB (PDF)

Download

Medicine details

Medicine name:
crovalimab (Piasky)
SMC ID:
SMC2728
Indication:

As monotherapy for the treatment of adult and paediatric patients 12 years of age or older with a weight of 40 kg and above with paroxysmal nocturnal haemoglobinuria (PNH):

  • In patients with haemolysis with clinical symptom(s) indicative of high disease activity.
  • In patients who are clinically stable after having been treated with a complement component 5 (C5) inhibitor for at least the past 6 months.
Pharmaceutical company
Roche
BNF chapter
Nutrition and blood
Submission type
Abbreviated
Status
Restricted
Date advice published
13 January 2025